These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25963090)

  • 21. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
    Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
    Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
    [No Abstract]   [Full Text] [Related]  

  • 22. Metronomic chemotherapy: A relook at its basis and rationale.
    Rajasekaran T; Ng QS; Tan DS; Lim WT; Ang MK; Toh CK; Chowbay B; Kanesvaran R; Tan EH
    Cancer Lett; 2017 Mar; 388():328-333. PubMed ID: 28003122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression-free survival: helpful biomarker or clinically meaningless end point?
    Venook AP; Tabernero J
    J Clin Oncol; 2015 Jan; 33(1):4-6. PubMed ID: 25366687
    [No Abstract]   [Full Text] [Related]  

  • 24. [Are there indications for adjuvant chemotherapy after excision of colorectal cancer?].
    Gérard A
    Pathol Biol (Paris); 1989 Nov; 37(9):990. PubMed ID: 2691974
    [No Abstract]   [Full Text] [Related]  

  • 25. Metronomic chemotherapy in metastatic colorectal cancer.
    Woo IS; Jung YH
    Cancer Lett; 2017 Aug; 400():319-324. PubMed ID: 28274890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
    Satoh T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
    [No Abstract]   [Full Text] [Related]  

  • 27. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
    Goldstein DA; El-Rayes BF
    Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current treatment benefits in advanced colorectal cancer.
    Scheithauer W
    Lancet Oncol; 2007 Oct; 8(10):857-9. PubMed ID: 17913652
    [No Abstract]   [Full Text] [Related]  

  • 30. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    Glimelius B; Dahl O; Cedermark B; Jakobsen A; Bentzen SM; Starkhammar H; Grönberg H; Hultborn R; Albertsson M; Påhlman L; Tveit KM;
    Acta Oncol; 2005; 44(8):904-12. PubMed ID: 16332600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab in the treatment of colorectal cancer.
    Goldberg RM; Venook AP; Schilsky RL
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):1-10; quiz 11-12. PubMed ID: 16170891
    [No Abstract]   [Full Text] [Related]  

  • 32. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
    Goldberg R
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
    [No Abstract]   [Full Text] [Related]  

  • 33. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies.
    Hubbard JM; Grothey A
    Nat Rev Clin Oncol; 2015 Feb; 12(2):73-4. PubMed ID: 25560533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New lessons from "old" chemotherapy in colorectal cancer.
    Grothey A; Sargent DJ
    J Clin Oncol; 2008 Oct; 26(28):4532-4. PubMed ID: 18824704
    [No Abstract]   [Full Text] [Related]  

  • 35. RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
    Wen-zhuo H; Liang-ping X
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26754849
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjuvant chemotherapy for colorectal cancer.
    Maughan TS
    Br J Cancer; 2001 Nov; 85(10):1422-4. PubMed ID: 11720422
    [No Abstract]   [Full Text] [Related]  

  • 37. [Leucovorin and 5-FU for advanced gastrointestinal cancer].
    Sasaki T; Maeda Y; Kobayashi T
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):440-6. PubMed ID: 10097740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
    Venook AP; Blanke CD; Niedzwiecki D; Lenz HJ; Taylor JR; Hollis DR; Sutherland S; Goldberg RM
    Clin Colorectal Cancer; 2007 May; 6(7):536-8. PubMed ID: 17553204
    [No Abstract]   [Full Text] [Related]  

  • 39. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
    Hurwitz HI; Lyman GH
    J Clin Oncol; 2012 Feb; 30(6):580-1. PubMed ID: 22253468
    [No Abstract]   [Full Text] [Related]  

  • 40. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.
    Ajani JA
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):10-2. PubMed ID: 14569840
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.